CNS Pharma Reports Received Approval From France Ethics Committee, Competent Authority For Potentially Pivotal Study Of Berubicin For Treatment Of Glioblastoma Multiforme
Company continues to drive global patient enrollment in pivotal study of Berubicin
HOUSTON, April 6, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a